CLINICAL LYMPHATIC MAPPING IN GYNECOLOGIC CANCERS. 2ND EDITION

CLINICAL LYMPHATIC MAPPING IN GYNECOLOGIC CANCERS. 2ND EDITION

Editorial:
CRC PRESS
Año de edición:
Materia
Ginecología
ISBN:
978-1-032-18643-6
Páginas:
158
N. de edición:
2
Idioma:
Inglés
Ilustraciones:
108
Disponibilidad:
Disponible en 2-3 semanas

Descuento:

-5%

Antes:

157,00 €

Despues:

149,15 €

Preface
1. The history of lymphatic mapping: a gynecologic perspective
2. Lymphatic anatomy: microanatomy and physiology
3. Lymphatic anatomy: lymphatics of the vulva
4. Lymphatic anatomy: lymphatics of the cervix
5. Lymphatic anatomy: lymphatics of the uterus
6. Lymphatic anatomy: lymphatics of the ovary
7. Lymphatic anatomy: lymphatics of the breast and axilla
8. Modalities of detection of sentinel nodes in lymphatic mapping
9. Ultrastaging of the sentinel node
10. Sentinel lymph node biopsy of the vulva
11. Sentinel lymph node mapping in cervical cancer
12. Sentinel lymph node mapping in breast cancer
13. Sentinel lymph node biopsy of the endometrium
14. Impact of sentinel lymph node mapping on quality of life
15. Radiation oncology considerations
16. Special considerations
17. Clinical trial design
Index

Lymphatic mapping techniques have proven to be useful to the early detection and safe treatment of endometrial and cervical cancers; however, the techniques have much of value to offer for breast cancer also and particularly for vulvar cancer, where there has been an explosion of interest and research. In the new edition of Clinical Lymphatic Mapping of Gynecologic Cancers, the techniques are fully explained, with consideration of the latest developments and technologies.

Authors
• Charles Levenback, MD is Professor and Deputy Chairman, Department of Gynecologic Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA, and formerly Chief Professionalism Officer. In 2017 he shared the Society of Gynecologic Oncology Innovation Award in recognition for his role in the development of sentinel lymph node biopsy in gynecologic oncology patients and his lead investigator role in multiple institutional and national clinical trials.
• Ate G.J. van der Zee, MD, PhD is Professor of Gynaecological Oncology and Vice President of the Board of Directors, University Medical Center Groningen, The Netherlands. He leads a world-wide consortium (GROINSS-V-II), which performs landmark clinical studies in vulvar cancer, and shared the SGO Innovation Award in 2017.
• Robert L. Coleman, MD, FACOG, FACS is Chief Scientific Officer, US Oncology Research, The US Oncology Network, McKesson Specialty Health, The Woodlands, TX, USA, and formerly Professor and Ann Rife Cox Chair of the Department of Gynecologic Oncology and Reproductive Medicine at the University of Texas MD Anderson Cancer Center and Executive Director of Cancer Network Research.